A carregar...
BMI1 Silencing Enhances Docetaxel Activity and Impairs Antioxidant Response in Prostate Cancer
The BMI1 oncogene promotes prostate cancer progression. High BMI1 expression predicts poor prognosis in prostate cancer (PC) patients. Recent evidence suggests that BMI1 may also play a role in Docetaxel chemoresistance. However, mechanisms and clinical significance of BMI1-related chemoresistance h...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3265034/ https://ncbi.nlm.nih.gov/pubmed/20568112 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.25522 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|